Implementation of Deconvolution Reporting Software (DRS) in Doping Control

Importance of the Topic

Routine screening in doping control relies heavily on gas chromatography–mass spectrometry (GC-MS) to detect a wide range of prohibited substances in athlete urine. Manual interpretation of complex full-scan data by multiple reviewers is time-consuming and resource-intensive. Implementing automated deconvolution and reporting tools can streamline workflows, reduce analyst workload, and maintain high reliability in identifying target compounds.

Objectives and Study Overview

This study evaluates the practical integration of the Deconvolution Reporting Software (DRS) within a full-scan GC-MS screening method for stimulants and narcotics. The goals were to determine sensitivity, optimize match factor thresholds, assess false positive/negative rates, and compare DRS performance against traditional dual-operator review.

Methodology and Instrumentation

Sample Preparation and Analysis:

• Urine extraction followed a validated single-step derivatization protocol.
• Negative urine was spiked with nine target compounds (10–500 ng/mL) to evaluate sensitivity.
• A library of over 100 reference compounds was constructed using two approaches: direct ChemStation capture and AMDIS-deconvoluted spectra.

Instrumentation:

• Agilent 6890 GC coupled to Agilent 5973 MSD
• MS data acquisition in full-scan mode
• DRS implemented within MSD ChemStation (Rev. D.03.00)
• Mass spectral deconvolution performed by AMDIS, with optional NIST library matching

Main Results and Discussion

Library Construction and Match Factors:

• ChemStation library entries contained hundreds of m/z values, while AMDIS-derived libraries used a limited set of high-certainty ions (e.g., 12 ions for amphetamine vs. 333).
• AMDIS libraries yielded significantly higher match factors (e.g., 98% vs. 36% for MDA at 500 ng/mL).

Cutoff Optimization:

• A match factor threshold of 65% and a retention time tolerance of ±6 s achieved detection of all nine test compounds at 100 ng/mL without false positives.

Routine Sample Screening:

• Across 1,366 samples, DRS reproduced all positive findings reported by two operators and identified three additional positives undetected in manual review.
• Case studies demonstrated DRS’s ability to resolve coeluting interferences (e.g., amphetamine in glycerol matrix) and uncover low-level targets masked in macro plots (e.g., methylphenidate, hydromorphone).
• Adaptation to SIM/scan methods is conceptually feasible but requires additional diagnostic ions and modified processing workflows.

Benefits and Practical Applications of the Method

Integrating DRS into routine screening protocols offers:

• Reduced analyst workload—one operator plus DRS can replace dual review
• Improved confidence in identification through deconvolution of overlapping peaks
• Robust detection at or below WADA MRPL values for stimulants and narcotics
• Flexible library management using AMDIS or direct instrument software

Future Trends and Potential Applications

Further developments may include:

• Full integration of SIM/scan deconvolution to cover low-level anabolic steroids
• Automated retention time locking and dynamic library updates
• Cross-platform compatibility with high-resolution MS and emerging chemometric tools
• Expanded forensic and clinical toxicology applications beyond doping control

Conclusion

The Deconvolution Reporting Software provides a reliable, efficient approach to GC-MS screening in doping control. By leveraging AMDIS deconvolution and custom libraries, DRS enhances identification accuracy, reduces false results, and streamlines laboratory workflows. With further refinement for SIM-based methods, DRS can become an indispensable tool for high-throughput forensic toxicology.

References

1. Ayotte C, Goudreault D, Charlebois A. Testing for Natural and Synthetic Anabolic Agents in Human Urine. J Chromatogr B. 1996;687:3–25.
2. Van Thuyne W, Van Eenoo P, Delbeke FT. Comprehensive Screening Method for the Qualitative Detection of Narcotics and Stimulants Using Single Step Derivatisation. J Chromatogr B. 2007;857:259–265.
3. Cone EJ, Heit HA, Caplan YH, Gourlay D. Evidence of Morphine Metabolism to Hydromorphone in Pain Patients Chronically Treated with Morphine. J Anal Toxicol. 2006;30:1–5.
4. Van Thuyne W, Van Eenoo P, Delbeke FT. Possibilities of SIM/Scan Analysis in Doping Control. In: Schänzer W, Geyer H, Gotzmann A, Mareck U, editors. Recent Advances in Doping Analysis. Vol 15. Köln; 2007. p. 227–234.